SCHEMBL3246912

SCHEMBL3246912

Clc1[c]ccc(CNc2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
FFAR1 O14842 2/20 0.44
ALDH1A1 P00352 2/20 0.40
ARG1 P05089 1/20 0.38
MAPK1 P28482 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
REN P00797 1/20 0.36
CHEK1 O14757 1/20 0.36
ROCK2 O75116 1/20 0.36
RPS6KA5 O75582 1/20 0.36
MAP4K4 O95819 1/20 0.36
CHEK2 O96017 1/20 0.36
PIM1 P11309 1/20 0.36
PRKACA P17612 1/20 0.36
RPS6KB1 P23443 1/20 0.36
AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242481 0.86 MAPT (0.43) MAPTMEN1KMT2AATML3MBTL1
SCHEMBL3246772 0.83 NPC1 (0.46) MAPTMEN1KMT2AL3MBTL1FFAR1
SCHEMBL3240341 0.81 LMNA (0.42) MAPTMEN1KMT2AL3MBTL1FFAR1
SCHEMBL3248749 0.77 HPGD (0.51) MAPTMEN1KMT2AL3MBTL1FFAR1
SCHEMBL11511690 0.74 MEN1 (0.60) MAPTMEN1KMT2AATML3MBTL1
SCHEMBL3249639 0.74 MAPT (0.43) MAPTMEN1KMT2AATML3MBTL1
SCHEMBL6306011 0.73 HTT (0.44) L3MBTL1ALDH1A1
SCHEMBL2500621 0.72 KDM4E (0.39) MAPTEPHX2
SCHEMBL3250946 0.72 MAPT (0.41) MAPTMEN1KMT2AATML3MBTL1
SCHEMBL3246891 0.72 MAPT (0.53) MAPTMEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP claimed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO claimed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP disclosed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO disclosed